Bruce M.
Psaty
MD
PhD
MPH
Education & Training
- PhD, English language and literature, Indiana University, Bloomington, IN (1979)
- MD, Indiana University School of Medicine, Indianapolis, IN (1981)
- Residency in Internal Medicine, Indiana University Medical Center, Indianapolis, IN (1984)
- MPH, University of Washington, Seattle, WA (1986)
Honors
- Research.com, 2nd edition, Best Medicine Scientist (#60 US, #85 world) and Best Scientist (#101 US, and #144 world) (2023)
- William J. Bremner Endowed Mentorship Award, UW Dept of Medicine (2023)
- Member, National Heart, Lung, and Blood Institute Board of External Experts (2018–2023)
- Named 1 of 75 UW’s Department of Medicine Changemakers (2022)
- University of Washington, School of Public Health Distinguished Alumni Award (2018)
- Designated Distinguished Scientist by the American Heart Association (2013)
- Elected to the Institute of Medicine of the National Academies of Science (2013)
- Member, National Heart, Lung, Blood Institute Advisory Council (2012–2017)
- Member, US Food and Drug Administration Science Board (2011–2018)
- Ancel Keys Memorial Lectureship, American Heart Association National Meeting (2009)
- School of Public Health and Community Medicine Outstanding Faculty Community Service Award (2005)
- University of Washington Outstanding Public Service Award for Work in Drug Safety (2005)
- Remington Methodology Lecturer, AHA Epidemiology and Prevention Council (2004)
Research
Bruce M. Psaty, MD, PhD is a Professor of Medicine, Epidemiology, and Health Services; Emeritus Co-Director of the Cardiovascular Health Research Unit at the University of Washington; and a general internist at Harborview Medical Center, Seattle, WA. He received his MD and PhD in English language and literature from Indiana University and his MPH in epidemiology from the University of Washington. His research interests include cardiovascular epidemiology, epidemiological methods, myocardial infarction, stroke, hypertension, diabetes, drug safety, pharmacoepidemiology, genetics, genomics, and pharmacogenetics. Dr Psaty is the principal investigator on several large epidemiologic studies and has had major roles as a cardiovascular disease epidemiologist at the coordinating centers of NIH-funded multi-center studies, including the Cardiovascular Health Study (CHS), the Multi-Ethnic Study of Atherosclerosis, and the Trans-Omics for Precision Medicine Program. In these settings and others, he has used case-control, cohort, clinical-trial, and meta-analytic methods to evaluate the risks and benefits of a variety of medications, including hormone therapy, non-steroidal anti-inflammatory agents, and drugs used to treat hypertension, diabetes, dyslipidemia, asthma, heart failure, atrial fibrillation, osteoporosis, chronic pain, and other conditions as well as drug-gene interactions that may influence the risk-benefit profile of selected medications. In 2008, Dr Psaty collaborated with investigators from other national and international cohort studies to establish the CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology) Consortium, which has published more than 1,250 papers on genome-wide association studies of a variety of phenotypes. Currently, he is also the PI of CHS as well as a large proteomics study in the setting of CHS. With more than 1,225 articles, editorials, and commentaries in the medical literature, Dr. Psaty publishes regularly and serves on the editorial board of several journals.
publication highlights
- Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW, Wagner EH, Furberg CD. The risk of myocardial infarction associated with anti-hypertensive drug therapies. JAMA 1995; 274: 620–625.
- Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: A network meta-analysis. JAMA 2003; 289: 2534–2544.
- Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: A case study based on documents from rofecoxib litigation. JAMA. 2008 Apr 16;299(15):1813–7.
- Psaty BM, O’Donnell CJ, Gudnason V, Kunetta KL, Folsom AR, Rotter JI, Uitterlinden AG, Harris TB, Witteman JCM, Boerwinkle E on behalf of the CHARGE Consortiu. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts. Circ Cardiovasc Genet 2009; 2: 73–80.
- Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, … Psaty BM#, Abecasis GR#, Chakravarti A#, Elliott P#, van Duijn CM#, Newton-Cheh C#, Levy D#, Caulfield MJ#, Johnson T#. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011 Sep 11;478(7367):103–9. #These authors contributed equally.